Regression of optic disc neovascularization in patients with Behçet's uveoretinitis after infliximab therapy.
OBJECTIVE
Optic disc neovascularization (NVD) in patients with Behçet's uveoretinitis is a relatively uncommon but severe complication that lacks standardized treatments. We report 2 cases of Behçet's uveoretinitis that achieved partial regression of NVD after infliximab therapy.


METHODS
Intravenous infliximab infusions were administrated to 2 immunosuppressive therapy-resistant Behçet's uveoretinitis patients with severe NVD accompanied by vitreous hemorrhage (both eyes in case 1 and the left eye in case 2 ). Best-corrected visual acuity, funduscopic findings, and fluorescein angiography were evaluated before and after the treatments.


RESULTS
After being switched to infliximab therapy, NVD in both cases stopped developing and regressed partially, as confirmed by fluorescein angiography and resolution of vitreous hemorrhage, which led to an improvement of the best-corrected visual acuity.


CONCLUSIONS
Results suggest that infliximab administration might be an effective treatment in NVD patients with Behçet's uveoretinitis.
Department of Ophthalmology and Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. kawaguchi.oph@tmd.ac.jp
Tatsushi
T
Kawaguchi
Sunao
S
Sugita
Yukiko
Y
Yamada
Masaru
M
Miyanaga
Manabu
M
Mochizuki
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001528:Behcet Syndrome / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005451:Fluorescein Angiography; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D009898:Optic Disk / Q000098:blood supply; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab